abstract: INTRODUCTION: @entity6 is a serious complication of pregnancy. We describe a case leading to uterine @entity1 associated with massive @entity4 . CASE PRESENTATION: A 34-year-old Caucasian Albanian @entity0 , gravida 2, para 1, was admitted to the emergency department of our hospital for acute @entity3 associated with profound secondary @entity2 . An anatomopathological diagnosis of @entity6 destruens was made. An urgent hysterectomy was performed after resuscitation procedures, applied due to the severe @entity2 and the abdominal drama accompanying the case. Intra-operatively, a uterus-saving procedure was found to be impossible, and hysterectomy remained the only surgical option. The uterine structures were sent for further microscopic evaluation. On histological examination, deep trophoblastic infiltration of the uterine wall was observed, justifying the surgeon's decision. Our @entity0 received blood transfusions and antibiotics. Her sutures were removed on the eighth postoperative day and she was discharged the following day in a stable condition. CONCLUSION: This case, describing a @entity0 with uterine @entity1 and massive @entity4 , illustrates a serious and potentially fatal complication of @entity5 . In such cases, surgery is essential, and hysterectomy may be the only viable option.

title: XXXX causing hemoperitoneum in the 26th week of pregnancy: a case report.

answer: @entity6


abstract: High-resolution electrophoretic methods and sensitive protein-detection techniques permit new approaches to understanding and diagnosis of the @entity3 . These approaches encompass: the search for protein alterations that represent primary mutations effects; observation of alterations in protein patterns due to secondary effects, as might occur in major metabolic pathway abnormalities; and identification of protein polymorphisms that are genetically linked to an @entity4 . With the aid of computer analysis of the electrophoretograms, all three approaches are being developed. Protein density and position are evaluated with an interactive computer program that requires that gel polypeptides be indexed by the investigator. Proteins on the gels are made visible with an inexpensive, rapid @entity1 stain, which can be used quantitatively. The @entity5 , one of a few @entity0 for which the molecular defect is known, was chosen for study with these techniques. Four hundred proteins were analyzed for positional or quantitative variation. Eleven significant (2p less than 0.01) quantitative differences were found in autoradiograms from gels of phytohemagglutinin-stimulated lymphocytes. Specific patterns of polypeptide variation are now being sought in an expanded clinical study primarily focusing on @entity2 . Large studies are required to establish the specificity of observed alterations. As the number and variety of analyses increase, a correlative catalog of molecular variation and polymorphism will be generated.

title: Quantitative two-dimensional protein electrophoresis for studies of XXXX .

answer: @entity3


abstract: Feed costs substantially affect the efficiency of poultry operations, justifying genetic improvement of feed utilization by selection. The current research was conducted to estimate genetic variance for the 4-wk feed conversion ratio (FCR) and its genetic correlations with BW, @entity1 ( @entity2 ), feed intake (FI), and @entity0 ( @entity0 ) in @entity3 . The data analyzed originated from a line selected for low FCR for 3 generations. In each generation, 35 sires and 70 dams were used as parents for the next generation. Body weight and @entity2 were recorded on a total of 1,226 individuals, whereas FCR, @entity0 , and FI were recorded on 505 family groups. The results showed that heritability estimates (  SE) of BW at 28 d of age and @entity2 between 7 and 28 d of age were 0.22    0.05 and 0.28    0.06, respectively. For FI, FCR, and @entity0 , significant genetic variances were estimated. Genetic correlations of FCR between 7 and 28 d of age with @entity2 and FI between 7 and 28 d of age were -0.45    0.09 and 0.24    0.08, respectively. This implies that a low FCR is genetically related to a high @entity2 and low FI. The genetic correlation between FCR from 7 to 28 d of age and @entity0 from 7 to 28 d of age was 0.26    0.08, indicating that the 2 alternative feed efficiency traits are genetically different traits, and that the correlated genetic response in one of them in response to selection on the other is likely to be only moderate. Genetic correlations of @entity0 from 7 to 28 d of age with @entity2 and FI between 7 and 28 d of age were 0.08    0.04 and 0.74    0.11, respectively. This reflects the fact that @entity0 is phenotypically independent of @entity2 , which tends to make the genetic correlation between @entity0 and @entity2 low as well. In conclusion, all the traits analyzed displayed significant genetic variance, allowing their genetic improvement by selection, yet the alternative feed utilization traits, FCR and @entity0 , displayed different genetic characteristics.

title: Genetic parameters for feed utilization traits in XXXX .

answer: @entity3


abstract: OBJECTIVE: To compare the effectiveness of elective single embryo transfer versus double embryo transfer on the outcomes of live birth, multiple live birth, miscarriage, @entity2 , term singleton birth, and low birth weight after fresh embryo transfer, and on the outcomes of cumulative live birth and multiple live birth after fresh and frozen embryo transfers. DESIGN: One stage meta-analysis of individual @entity0 data. DATA SOURCES: A systematic review of English and non-English articles from Medline, Embase, and the Cochrane Central Register of Controlled Trials (up to 2008). Additional studies were identified by contact with clinical experts and searches of bibliographies of all relevant primary articles. Search terms included embryo transfer, randomised controlled trial, controlled clinical trial, single embryo transfer, and double embryo transfer. Review methods Comparisons of the clinical effectiveness of cleavage stage (day 2 or 3) elective single versus double embryo transfer after fresh or frozen @entity1 ( @entity1 ) or intracytoplasmic sperm injection (ICSI) treatments were included. Trials were included if the intervention differed only in terms of the intended number of embryos to be transferred. Trials that involved only blastocyst (day five) transfers were excluded. RESULTS: Individual @entity0 data were received for every @entity0 recruited to all eight eligible trials (n=1367). A total of 683 and 684 @entity0 randomised to the single and double embryo transfer arms, respectively, were included in the analysis. Baseline characteristics in the two groups were comparable. The overall live birth rate in a fresh @entity1 cycle was lower after single (181/683, 27%) than double embryo transfer (285/683, 42%) (adjusted odds ratio 0.50, 95% confidence interval 0.39 to 0.63), as was the multiple birth rate (3/181 (2%) v 84/285 (29%)) (0.04, 0.01 to 0.12). An additional frozen single embryo transfer, however, resulted in a cumulative live birth rate not significantly lower than the rate after one fresh double embryo transfer (132/350 (38%) v 149/353 (42%) (0.85, 0.62 to 1.15), with a minimal cumulative risk of multiple birth (1/132 (1%) v 47/149 (32%)). The odds of a term singleton birth (that is, over 37 weeks) after elective single embryo transfer was almost five times higher than the odds after double embryo transfer (4.93, 2.98 to 8.18). CONCLUSIONS: Elective single embryo transfer results in a higher chance of delivering a term singleton live birth compared with double embryo transfer. Although this strategy yields a lower pregnancy rate than a double embryo transfer in a fresh @entity1 cycle, this difference is almost completely overcome by an additional frozen single embryo transfer cycle. The multiple pregnancy rate after elective single embryo transfer is comparable with that observed in spontaneous pregnancies.

title: Clinical effectiveness of elective single versus double embryo transfer: meta-analysis of individual XXXX data from randomised trials.

answer: @entity0


abstract: PURPOSE: To compare postoperative changes in apparent photopic and mesopic pupil size and centration in relation to @entity2 landmarks after @entity1 surgery. SETTING: LaserVision.gr Clinical and Research Eye Institute, Athens, Greece. DESIGN: Prospective consecutive case study. METHODS: Pupils were imaged for pupil size and corneal vertex location before and 1-month after @entity1 surgery. Digital analysis of pupil images was used to determine the Cartesian coordinates (nasal-temporal, horizontal @entity3 , superior-inferior, vertical @entity3 ) of the first Purkinje reflection point  (approximating the corneal intersection of the @entity0 [corneal vertex]) to the pupil geometric center (approximating the corneal intersection of the line of sight [corneal apex]). Pupil size changes were measured, and the correlation between vertex-to-apex shift changes and postoperative pupil centroid shift was evaluated. RESULTS: The study evaluated 40 eyes. The pupil size (diameter) change corresponded to a relative reduction of -9.8% for photopic pupils and -9.1% for mesopic pupils; the difference was statistically significant (P = .045 and P = .011, respectively). Also, there was a reduction in the centroid shift (all eyes) from a mean of 0.12  mm preoperatively to 0.05  mm postoperatively as a result of the postoperative minus temporal horizontal difference between the corneal vertex and the apex. CONCLUSIONS: Cataract extraction surgery appears to affect pupil size and centration. Specifically, a smaller pupil and less temporal shift were recorded. These data may have clinical relevance in targeted intraoperative intraocular lens centration. FINANCIAL DISCLOSURE: Dr. Kanellopoulos is a consultant to Alcon Surgical, Inc., Wavelight Laser Technologie AG, Allergan, Avedro, Inc., and i-Optics Corp. No author has a financial or proprietary interest in any material or method mentioned.

title: Digital pupillometry and centroid shift changes after XXXX surgery.

answer: @entity1


abstract: PURPOSE: To compare the @entity2 , @entity1 , undesired movement, and cooperation between @entity0 receiving oral @entity5 or intravenous (IV) @entity4 for conscious sedation during @entity3 surgery under topical anesthesia. SETTING: Ambulatory surgical center, Honolulu, Hawaii, USA. DESIGN: Prospective randomized controlled trial. METHODS: @entity0 having first-time @entity3 extraction with topical anesthesia were randomized to receive sedation with oral @entity5 30  minutes before surgery or IV @entity4 immediately preceding surgery. The outcomes of @entity2 , @entity1 , undesired movement, and poor cooperation were observed by the surgeon and recorded during surgery. RESULTS: One hundred fifty-six @entity3 surgeries were included, 83 in the IV @entity4 group and 73 in the oral @entity5 group. Twenty-four @entity0 (29%) in the IV group and 7 @entity0 (10%) in the oral group showed undesired movement (P  <  .02). Seven @entity0 (8%) in the IV group and 2 @entity0 (3%) in the oral group showed poor cooperation (P >  .05). Fifteen @entity0 (18%) in the IV  group and 9 @entity0 (12%) in the oral group had @entity1 (P >  .05). Three @entity0 (4%) in the  IV group and 3 @entity0 (4%) in the oral group experienced @entity2 (P >  .05). CONCLUSIONS: Fewer @entity0 receiving oral @entity5 30  minutes before @entity3 surgery than @entity0 receiving IV @entity4 immediately preceding surgery showed undesired movement during surgery. There was no statistically significant difference in the number of @entity0 showing poor cooperation or experiencing @entity2 or @entity1 between the 2 groups. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.

title: Oral XXXX versus intravenous @entity4 for conscious sedation during @entity3 surgery performed using topical anesthesia.

answer: @entity5


abstract: PURPOSE: To compare the @entity2 , @entity1 , undesired movement, and cooperation between @entity0 receiving oral @entity5 or intravenous (IV) @entity4 for conscious sedation during @entity3 surgery under topical anesthesia. SETTING: Ambulatory surgical center, Honolulu, Hawaii, USA. DESIGN: Prospective randomized controlled trial. METHODS: @entity0 having first-time @entity3 extraction with topical anesthesia were randomized to receive sedation with oral @entity5 30  minutes before surgery or IV @entity4 immediately preceding surgery. The outcomes of @entity2 , @entity1 , undesired movement, and poor cooperation were observed by the surgeon and recorded during surgery. RESULTS: One hundred fifty-six @entity3 surgeries were included, 83 in the IV @entity4 group and 73 in the oral @entity5 group. Twenty-four @entity0 (29%) in the IV group and 7 @entity0 (10%) in the oral group showed undesired movement (P  <  .02). Seven @entity0 (8%) in the IV group and 2 @entity0 (3%) in the oral group showed poor cooperation (P >  .05). Fifteen @entity0 (18%) in the IV  group and 9 @entity0 (12%) in the oral group had @entity1 (P >  .05). Three @entity0 (4%) in the  IV group and 3 @entity0 (4%) in the oral group experienced @entity2 (P >  .05). CONCLUSIONS: Fewer @entity0 receiving oral @entity5 30  minutes before @entity3 surgery than @entity0 receiving IV @entity4 immediately preceding surgery showed undesired movement during surgery. There was no statistically significant difference in the number of @entity0 showing poor cooperation or experiencing @entity2 or @entity1 between the 2 groups. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.

title: Oral @entity5 versus intravenous @entity4 for conscious sedation during XXXX surgery performed using topical anesthesia.

answer: @entity3


abstract: PURPOSE: To compare the @entity2 , @entity1 , undesired movement, and cooperation between @entity0 receiving oral @entity5 or intravenous (IV) @entity4 for conscious sedation during @entity3 surgery under topical anesthesia. SETTING: Ambulatory surgical center, Honolulu, Hawaii, USA. DESIGN: Prospective randomized controlled trial. METHODS: @entity0 having first-time @entity3 extraction with topical anesthesia were randomized to receive sedation with oral @entity5 30  minutes before surgery or IV @entity4 immediately preceding surgery. The outcomes of @entity2 , @entity1 , undesired movement, and poor cooperation were observed by the surgeon and recorded during surgery. RESULTS: One hundred fifty-six @entity3 surgeries were included, 83 in the IV @entity4 group and 73 in the oral @entity5 group. Twenty-four @entity0 (29%) in the IV group and 7 @entity0 (10%) in the oral group showed undesired movement (P  <  .02). Seven @entity0 (8%) in the IV group and 2 @entity0 (3%) in the oral group showed poor cooperation (P >  .05). Fifteen @entity0 (18%) in the IV  group and 9 @entity0 (12%) in the oral group had @entity1 (P >  .05). Three @entity0 (4%) in the  IV group and 3 @entity0 (4%) in the oral group experienced @entity2 (P >  .05). CONCLUSIONS: Fewer @entity0 receiving oral @entity5 30  minutes before @entity3 surgery than @entity0 receiving IV @entity4 immediately preceding surgery showed undesired movement during surgery. There was no statistically significant difference in the number of @entity0 showing poor cooperation or experiencing @entity2 or @entity1 between the 2 groups. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.

title: Oral @entity5 versus intravenous XXXX for conscious sedation during @entity3 surgery performed using topical anesthesia.

answer: @entity4


abstract: OBJECTIVE: To describe the experience with surgical treatment of @entity5 via a fully transnasal endoscopic approach. METHODS: Clinical records of 375 cases with @entity5 underwent pure endoscopic operations between December 2006 and December 2009 were carefully assembled. Among 375 pure endoscopic operations of @entity5 , 201 cases were nonfunctional @entity2 and 174 cases were functional @entity2 . There were 27 giant @entity5 (7.2%) and 41 @entity5 invaded cavernous sinus (10.9%). Intraoperative 1.5 T MRI and neuro-navigation system were used during some operations. The postoperative and follow-up data of @entity0 were analyzed. RESULTS: There were 234 (79.3%) cases of total resection, 56 (19.0%) cases of subtotal resection, 5 (1.7%) cases of partial resection. Sixty-eight @entity0 had vision improved in 73 @entity0 with vision decreasing before operation. Sixty-eight (77.3%) @entity0 got normal endocrine in 88 @entity12 @entity0 . Fifty-five (84.1%) @entity0 got normal @entity8 in 63 @entity0 with @entity11 . Eighteen (78.2%) @entity0 got normal in 23 @entity0 with corticotrophinoma. These was no death case in this group. One case (0.3%) suffered @entity4 . Transient @entity1 occurred in 2 cases (0.5%). Transient @entity9 or abducens nerve occurred in 7 cases of operations involved cavernous sinus. Three (0.8%) @entity0 had @entity3 . Two @entity0 (0.5%) suffered from @entity10 but none underwent operation to repair. Fourteen @entity0 (3.7%) had transient @entity7 . Six @entity0 (1.6%) had @entity6 . CONCLUSIONS: Trans-nasal endoscopy provides a new device for operation of @entity5 which is effective and safe. Comparing with microscope, endoscopic visual field is clearer, closer and wider.

title: [Pure endoscopic endonasal transsphenoidal approach for 375 XXXX ].

answer: @entity5


abstract: OBJECTIVE: To explore and evaluate the methodology of neuro-endoscope assisted @entity3 in @entity2 with @entity1 . METHODS: Between January 2007 to January 2008, 8 @entity0 underwent neuro-endoscope assisted @entity3 , including 2 male @entity0 and 6 female @entity0 (aged 13 to 52 years). During the operations, the surgical fields were lightened by the illuminator of endoscope. All the manipulations were done outside the sheath of neuroendoscope. The decompression bone window was about 2.0 cm   2.0 cm. After the @entity4 was cleared thoroughly, dura were opened in 6 cases and intact in 2 cases. RESULTS: There were no complications observed in this study. Seven @entity0 were determined as excellent in recovery according to the Tator criteria because of apparent improvements in superficial sensation. Five of the seven @entity0 had improvements in muscle strength. One @entity0 was assessed as good because of stable symptom without deterioration. CONCLUSION: Neuro-endoscope assisted @entity3 is a potential technique worthy of employing in the mini-invasive neurosurgical technology.

title: [The preliminary study of using neuro-endoscope assisted @entity3 to treat XXXX with @entity1 ].

answer: @entity2


abstract: OBJECTIVE: To explore and evaluate the methodology of neuro-endoscope assisted @entity3 in @entity2 with @entity1 . METHODS: Between January 2007 to January 2008, 8 @entity0 underwent neuro-endoscope assisted @entity3 , including 2 male @entity0 and 6 female @entity0 (aged 13 to 52 years). During the operations, the surgical fields were lightened by the illuminator of endoscope. All the manipulations were done outside the sheath of neuroendoscope. The decompression bone window was about 2.0 cm   2.0 cm. After the @entity4 was cleared thoroughly, dura were opened in 6 cases and intact in 2 cases. RESULTS: There were no complications observed in this study. Seven @entity0 were determined as excellent in recovery according to the Tator criteria because of apparent improvements in superficial sensation. Five of the seven @entity0 had improvements in muscle strength. One @entity0 was assessed as good because of stable symptom without deterioration. CONCLUSION: Neuro-endoscope assisted @entity3 is a potential technique worthy of employing in the mini-invasive neurosurgical technology.

title: [The preliminary study of using neuro-endoscope assisted XXXX to treat @entity2 with @entity1 ].

answer: @entity3


abstract: OBJECTIVE: To explore and evaluate the methodology of neuro-endoscope assisted @entity3 in @entity2 with @entity1 . METHODS: Between January 2007 to January 2008, 8 @entity0 underwent neuro-endoscope assisted @entity3 , including 2 male @entity0 and 6 female @entity0 (aged 13 to 52 years). During the operations, the surgical fields were lightened by the illuminator of endoscope. All the manipulations were done outside the sheath of neuroendoscope. The decompression bone window was about 2.0 cm   2.0 cm. After the @entity4 was cleared thoroughly, dura were opened in 6 cases and intact in 2 cases. RESULTS: There were no complications observed in this study. Seven @entity0 were determined as excellent in recovery according to the Tator criteria because of apparent improvements in superficial sensation. Five of the seven @entity0 had improvements in muscle strength. One @entity0 was assessed as good because of stable symptom without deterioration. CONCLUSION: Neuro-endoscope assisted @entity3 is a potential technique worthy of employing in the mini-invasive neurosurgical technology.

title: [The preliminary study of using neuro-endoscope assisted @entity3 to treat @entity2 with XXXX ].

answer: @entity1


abstract: OBJECTIVE: To compare the relief effect of @entity5 , @entity4 and @entity2 on radial @entity3 in elderly @entity0 with @entity1 . METHODS: Sixty @entity0 aged beyond 70 years underwent coronary artery bypass grafting (CABG) with autologous radial artery from July 2009 to March 2010. Redundant radial artery was collected and the relief function of different drugs was evaluated through "organ bath" technique in vitro. All the @entity0 were randomly divided into 3 groups based on different antispasmodic drugs: @entity5 , @entity4 and @entity2 . Thirty seconds free blood flow of radial artery and hemodynamic parameters (heart rate, mean arterial pressure and central venous pressure) were assessed before and after intra-radial administration of @entity5 , @entity4 and @entity2 in vivo. RESULTS: All three drugs could relieve radial @entity3 in different levels and the eventual relief rate was over 80%. Only @entity2 could relax radial artery completely, the relief capacity of @entity2 , @entity5 and @entity4 decreased in order. There was no significant difference in the hemodynamic parameters before and after the injection. Blood flow of radial artery increased in @entity2 group [(42    10) ml/30 s vs. (28    7) ml/30 s, P < 0.05] while there was no significant difference in @entity5 [(23    10) ml/30 s vs. (25    8) ml/30 s, P > 0.05] and @entity4 group [(25    10) ml/30 s vs. (24    9), P > 0.05]. CONCLUSIONS: @entity2 could relieve @entity3 of radial artery effectively and increased blood flow. @entity2 is the suitable antispasmodic drug for radial artery in the elderly @entity0 with @entity1 compare with @entity5 and @entity4 .

title: [Experimental study on the option of antispasmodic drugs for radial artery in elderly @entity0 with XXXX ].

answer: @entity1


abstract: OBJECTIVE: To compare the relief effect of @entity5 , @entity4 and @entity2 on radial @entity3 in elderly @entity0 with @entity1 . METHODS: Sixty @entity0 aged beyond 70 years underwent coronary artery bypass grafting (CABG) with autologous radial artery from July 2009 to March 2010. Redundant radial artery was collected and the relief function of different drugs was evaluated through "organ bath" technique in vitro. All the @entity0 were randomly divided into 3 groups based on different antispasmodic drugs: @entity5 , @entity4 and @entity2 . Thirty seconds free blood flow of radial artery and hemodynamic parameters (heart rate, mean arterial pressure and central venous pressure) were assessed before and after intra-radial administration of @entity5 , @entity4 and @entity2 in vivo. RESULTS: All three drugs could relieve radial @entity3 in different levels and the eventual relief rate was over 80%. Only @entity2 could relax radial artery completely, the relief capacity of @entity2 , @entity5 and @entity4 decreased in order. There was no significant difference in the hemodynamic parameters before and after the injection. Blood flow of radial artery increased in @entity2 group [(42    10) ml/30 s vs. (28    7) ml/30 s, P < 0.05] while there was no significant difference in @entity5 [(23    10) ml/30 s vs. (25    8) ml/30 s, P > 0.05] and @entity4 group [(25    10) ml/30 s vs. (24    9), P > 0.05]. CONCLUSIONS: @entity2 could relieve @entity3 of radial artery effectively and increased blood flow. @entity2 is the suitable antispasmodic drug for radial artery in the elderly @entity0 with @entity1 compare with @entity5 and @entity4 .

title: [Experimental study on the option of antispasmodic drugs for radial artery in elderly XXXX with @entity1 ].

answer: @entity0


abstract: OBJECTIVE: To analyze the clinical characteristics and the surgical treatment strategy of cervical @entity2 . METHODS: From March 2006 to October 2009, 31 cases of cervical @entity2 were treated. According to the clinical features and imaging findings, different treatment methods were used. There were 9 @entity0 in operation group, including 4 male and 5 female @entity0 , aged from 17 to 72 years (average age of 35 years). Among them, 5 cases were idiopathic @entity2 and 4 cases were caused by laminectomy or other reasons. There were 22 @entity0 in conservative treatment group, including 11 male and 11 female @entity0 , aged from 14 to 40 years (average age of 29 years), who were all @entity4 . Before and 1 week after operation, clinical assessment were taken for the @entity0 in operation group using Spinal Cord Injuries Classification Standard of American @entity3 Association (AISA). During the periodic review, the anteroposterior, normal sagittal films of cervical spine were taken. At 1 week and every 6 months after operation, MRI films were also taken. These films were studied to evaluate the effects of the operations. In the conservative group, assessment of treatment results by studying anteroposterior and normal lateral views of cervical spine were were taken every month. The clinical characteristics and the surgical treatment strategies of these @entity0 were analyzed. RESULTS: In operation group, 9 cases were followed up for 6 to 18 months, all @entity0 did not failed in internal fixation and fusion. AISA neurological score and neurological function significantly improved. Three days after operation the average Cobb angle was -1.29    (preoperative 54.24   ). In conservative group, the average Cobb angle was -5.41    (before treatment 11.20   ) 4 months after the treatment. The symptoms of neck shoulder and back @entity1 disappeared, and all @entity0 were followed up for 3 to 24 months, with no recurrence of symptoms. CONCLUSIONS: In the early period of cervical @entity2 , adopt postural therapy, plaster braces to correct an imbalance in cervical spine biomechanics can prevent deformity development. According to @entity0 ' clinical characteristics, choosing individual treatment programs can correct the severe cervical @entity2 and achieve good outcome.

title: [The clinical features and surgical treatment strategies of cervical XXXX ].

answer: @entity2


abstract: UNASSIGNED: This study aimed to evaluate the efficacy and safety of the @entity4 - @entity2 -rituximab regimen for young physically fit @entity0 with @entity3 in the "real-life" setting. We specifically focused on the impact of dose reduction on @entity0 outcomes. The @entity0 cohort consisted of 128 @entity0 with @entity3 ( <=70 years) treated at 10 Israeli centers with frontline @entity4 - @entity2 -rituximab. We defined reduced chemotherapy as  <=2/3 of the total indicated dose. @entity0 treated with rituximab were divided into two groups and compared, those who received full dosages of 375mg/m2 or 500mg/m2 and @entity0 given less than six cycles with either dose. Overall and clinical complete response rates (92.8% and 70.4%) as well as @entity1 and overall survival (median not reached at 6 years) were similar to other reported clinical trials, but progression free survival, was shorter (42.5 months). Almost 50% of @entity0 had some dose reduction of chemotherapy, 21% receiving  <=2/3 of the indicated dose, while close to 30% did not complete six cycles of rituximab. Reduced doses of chemotherapy and rituximab were independently associated with shorter progression free survival (hazard ratio-3.6, p<0.0001 for reduced chemotherapy; hazard ratio-2.5, p=0.003 for incomplete-treatment with rituximab). Achieving a complete response was associated with longer overall survival but was not linked to the given dose of chemoimmunotherapy. In younger physically fit @entity0 , frontline @entity4 - @entity2 -rituximab therapy in the "real-life" setting, achieves long remissions (albeit shorter than in clinical trials) and prolonged overall survival. However, dose reductions are commonly administered and may impact outcome.

title: Efficacy and safety of frontline therapy with "FCR" regimen for @entity3 outside clinical trials: the Israeli XXXX study group experience.

answer: @entity3


abstract: UNASSIGNED: This study aimed to evaluate the efficacy and safety of the @entity4 - @entity2 -rituximab regimen for young physically fit @entity0 with @entity3 in the "real-life" setting. We specifically focused on the impact of dose reduction on @entity0 outcomes. The @entity0 cohort consisted of 128 @entity0 with @entity3 ( <=70 years) treated at 10 Israeli centers with frontline @entity4 - @entity2 -rituximab. We defined reduced chemotherapy as  <=2/3 of the total indicated dose. @entity0 treated with rituximab were divided into two groups and compared, those who received full dosages of 375mg/m2 or 500mg/m2 and @entity0 given less than six cycles with either dose. Overall and clinical complete response rates (92.8% and 70.4%) as well as @entity1 and overall survival (median not reached at 6 years) were similar to other reported clinical trials, but progression free survival, was shorter (42.5 months). Almost 50% of @entity0 had some dose reduction of chemotherapy, 21% receiving  <=2/3 of the indicated dose, while close to 30% did not complete six cycles of rituximab. Reduced doses of chemotherapy and rituximab were independently associated with shorter progression free survival (hazard ratio-3.6, p<0.0001 for reduced chemotherapy; hazard ratio-2.5, p=0.003 for incomplete-treatment with rituximab). Achieving a complete response was associated with longer overall survival but was not linked to the given dose of chemoimmunotherapy. In younger physically fit @entity0 , frontline @entity4 - @entity2 -rituximab therapy in the "real-life" setting, achieves long remissions (albeit shorter than in clinical trials) and prolonged overall survival. However, dose reductions are commonly administered and may impact outcome.

title: Efficacy and safety of frontline therapy with "FCR" regimen for XXXX outside clinical trials: the Israeli @entity3 study group experience.

answer: @entity3


abstract: BACKGROUND: @entity3 ( @entity3 ) is a rare complication in @entity2 with high mortality. Numerous case reports and one case series of 3 @entity0 report the benefit of @entity4 (STS) for treatment of @entity3 . The purpose of this evaluation was to examine the response to a STS-based treatment approach in @entity0 with @entity3 with 1 year follow up. METHODS: A retrospective case series of 6 consecutive @entity0 from Manitoba, Canada who met predefined diagnostic criteria for @entity3 and received STS between 2006 and 2008 were included. STS responders were defined as improvement in at least one of the following three parameters: @entity1 severity, wound size and diagnostic imaging/radiography. Mortality, STS dose, duration, adverse events and cost were also collected. RESULTS: Four @entity0 were classified as responders. The 2 responders who survived at 1 year of follow-up demonstrated an improvement in all 3 parameters examined including an improvement in their follow-up diagnostic imaging results within the first 4 - 6 weeks of STS treatment. At 1 year of follow-up, 3 @entity0 died. CONCLUSION: Using an STS-based multifaceted treatment approach for @entity3 , 4 @entity0 responded but 3 of 6 @entity0 died within 1 year. Further larger prospective studies are needed to delineate STS responders from non-responders.

title: XXXX -based treatment in @entity3 : a consecutive case series.

answer: @entity4


abstract: BACKGROUND: @entity3 ( @entity3 ) is a rare complication in @entity2 with high mortality. Numerous case reports and one case series of 3 @entity0 report the benefit of @entity4 (STS) for treatment of @entity3 . The purpose of this evaluation was to examine the response to a STS-based treatment approach in @entity0 with @entity3 with 1 year follow up. METHODS: A retrospective case series of 6 consecutive @entity0 from Manitoba, Canada who met predefined diagnostic criteria for @entity3 and received STS between 2006 and 2008 were included. STS responders were defined as improvement in at least one of the following three parameters: @entity1 severity, wound size and diagnostic imaging/radiography. Mortality, STS dose, duration, adverse events and cost were also collected. RESULTS: Four @entity0 were classified as responders. The 2 responders who survived at 1 year of follow-up demonstrated an improvement in all 3 parameters examined including an improvement in their follow-up diagnostic imaging results within the first 4 - 6 weeks of STS treatment. At 1 year of follow-up, 3 @entity0 died. CONCLUSION: Using an STS-based multifaceted treatment approach for @entity3 , 4 @entity0 responded but 3 of 6 @entity0 died within 1 year. Further larger prospective studies are needed to delineate STS responders from non-responders.

title: @entity4 -based treatment in XXXX : a consecutive case series.

answer: @entity3


abstract: OBJECTIVE/BACKGROUND: @entity2 ( @entity2 ) repair of an aortic @entity2 extending to the iliac artery remains a challenge. Interventional occlusion of the internal iliac artery (IIA) intending to create a distal landing zone in the external iliac artery is a common approach with inherent morbidity (e.g., buttock claudication, @entity1 ). Alternatively, iliac side-branched stent grafts can maintain pelvic blood supply, but the applicability is limited. The objective was to investigate the morphological applicability of the Cook Zenith branched graft (ZBIS) among @entity0 with aorto-iliac or isolated @entity3 . METHODS: This was a retrospective single centre analysis of 66 @entity0 (60 @entity0 ; median age 74 years, range 53-90 years) undergoing repair of aorto- @entity3 (open repair, IIA occlusion prior to @entity2 and ZBIS) between January 2008 and December 2012. All available computed tomography angiograms with post-processing imaging were compared with the criteria for morphological applicability to (i) the manufacturer's instruction for use (IFU), and (ii) to criteria published in the literature, as well as (iii) to the institutional protocol. RESULTS: In 66 @entity0 , 88 targeted @entity3 were studied. Of these, 36/88 (40.9%) were compliant with the manufacturer's IFU, 35/88 (39.8%) were compliant with the published criteria, and 51/88 (58.0%) were compliant with the in house protocol. The most common morphological exclusion criterion was an @entity3 . CONCLUSION: In the present cohort with aorto-iliac @entity2 , a maximum of 58% could have been treated with an iliac side branch based on the current experience. In particular, an @entity3 seems to be a limiting factor for the use of the iliac side-branched stent graft.

title: @entity2 Repair of XXXX with an Iliac Side-branched Stent graft: Studying the Morphological Applicability of the Cook Device.

answer: @entity2


abstract: OBJECTIVE/BACKGROUND: @entity2 ( @entity2 ) repair of an aortic @entity2 extending to the iliac artery remains a challenge. Interventional occlusion of the internal iliac artery (IIA) intending to create a distal landing zone in the external iliac artery is a common approach with inherent morbidity (e.g., buttock claudication, @entity1 ). Alternatively, iliac side-branched stent grafts can maintain pelvic blood supply, but the applicability is limited. The objective was to investigate the morphological applicability of the Cook Zenith branched graft (ZBIS) among @entity0 with aorto-iliac or isolated @entity3 . METHODS: This was a retrospective single centre analysis of 66 @entity0 (60 @entity0 ; median age 74 years, range 53-90 years) undergoing repair of aorto- @entity3 (open repair, IIA occlusion prior to @entity2 and ZBIS) between January 2008 and December 2012. All available computed tomography angiograms with post-processing imaging were compared with the criteria for morphological applicability to (i) the manufacturer's instruction for use (IFU), and (ii) to criteria published in the literature, as well as (iii) to the institutional protocol. RESULTS: In 66 @entity0 , 88 targeted @entity3 were studied. Of these, 36/88 (40.9%) were compliant with the manufacturer's IFU, 35/88 (39.8%) were compliant with the published criteria, and 51/88 (58.0%) were compliant with the in house protocol. The most common morphological exclusion criterion was an @entity3 . CONCLUSION: In the present cohort with aorto-iliac @entity2 , a maximum of 58% could have been treated with an iliac side branch based on the current experience. In particular, an @entity3 seems to be a limiting factor for the use of the iliac side-branched stent graft.

title: XXXX Repair of @entity2 with an Iliac Side-branched Stent graft: Studying the Morphological Applicability of the Cook Device.

answer: @entity2


abstract: Fourteen @entity0 , 4 males and 10 females, with @entity1 ( @entity1 ) were treated between July 1980 and June 1986. None of them had an affected sibling with a similar disorder. @entity4 was the most prominent symptom in all cases. @entity10 was present in 13 cases, @entity16 , @entity13 and @entity11 in 8, @entity6 or pleural effusion on chest X-ray in 8, @entity7 in 6, and @entity2 in 5 out of the 14 cases. @entity17 ( @entity17 ) was seen in 13 cases and this occurred within two weeks from onset in 6 cases. @entity15 , abnormal results of liver function tests, @entity18 and hypocholesterolemia were common. The diagnosis was made for all 14 cases by characteristic clinical symptoms, signs, and bone marrow findings. In 8 cases, biopsy or autopsy specimens confirmed the diagnosis. Two @entity0 died prior to chemotherapy. Twelve @entity0 were treated with @entity8 , @entity9 , @entity12 and @entity5 (ACOP). Complete response (CR) was achieved in five @entity0 , and another two @entity0 attained CR after subsequent treatment with other combinations including @entity14 . These 7 complete responders are now alive and free of disease 11+ to 70+ months (median, 50+ months) from the onset of disease. All partial and non-responders died within 6 months with a median survival of 20 days. Among several clinical features as prognostic indicators, @entity2 , @entity7 , and @entity17 occurring within 2 weeks were significantly related to poor outcome. Although @entity1 is an @entity3 with a poor prognosis, prompt diagnosis and early treatment with intensive systemic combination chemotherapy should further improve the outcome.

title: [Clinical features and therapeutic results in 14 cases of XXXX in childhood].

answer: @entity1


abstract: Twenty-one mildly asthmatic volunteers were exposed to 0, 0.3, 1.0, and 3.0 ppm @entity3 ( @entity2 ) in purified background air in an environmental control chamber. Exposures were separated by 1-wk periods and occurred in random order. Each lasted 1 hr and included three 10-min bouts of moderately heavy exercise (mean ventilation rate 41 L/min). Exposure temperature was near 22 degrees C and relative humidity near 50%. Specific airway resistance and maximal forced expiratory performance were measured preexposure, after the initial exercise, and near the end of exposure. Bronchial reactivity was assessed immediately following exposure, by normocapnic hyperventilation with subfreezing air. Symptoms were recorded on questionnaires before, during, and for 1-wk after each exposure. Exercise induced significant bronchoconstriction regardless of @entity2 level. No statistically significant untoward response to @entity2 was observed at any exposure concentration. This negative finding agrees with our previous results, but contrasts with findings elsewhere of @entity1 after exposure to 0.3 ppm. The discrepancy is presently unexplained, but it may relate to different severity of @entity0 in different subject groups.

title: Dose-response study of asthmatic volunteers exposed to XXXX during intermittent exercise.

answer: @entity3


abstract: OBJECTIVE: To assess the impact and results of treatment of @entity3 in the general population, we conducted a population-based, nation-wide study on 3,585 @entity3 @entity0 diagnosed between 1989 and 2012 in the Netherlands. METHODS: @entity0 demographics were obtained from the Netherlands Cancer Registry. Information on age, gender, year of diagnosis, first treatment and date of @entity1 were recorded. @entity2 ( @entity2 ) was adjusted for @entity1 rates in the normal population. RESULTS: Incidence in males decreased slightly from 1.2 per 100.000 @entity0 years (PY) in 1989-2000 to 0.9 in 2001-2012. For females, incidence remained stable with 0.7 per 100.000 PY in both periods. Incidence was age dependent and highest in males in the last decades of life. Treatment before 2000 mainly consisted of chemotherapy, while after 2007 TKI use was 88%. Five-year relative survival was only 36% before the introduction of TKIs but significantly increased to79% after the introduction of TKI. CONCLUSIONS: This study gives insight in @entity3 incidence, treatment and survival in routine care in the Netherlands. Although @entity2 improved since the introduction of TKIs, there is still room for further improvement. This article is protected by copyright. All rights reserved.

title: XXXX in The Netherlands: a Population-Based Study on Incidence, Treatment and Survival in 3,585 @entity0 from 1989-2012.

answer: @entity3


abstract: OBJECTIVE: To assess the impact and results of treatment of @entity3 in the general population, we conducted a population-based, nation-wide study on 3,585 @entity3 @entity0 diagnosed between 1989 and 2012 in the Netherlands. METHODS: @entity0 demographics were obtained from the Netherlands Cancer Registry. Information on age, gender, year of diagnosis, first treatment and date of @entity1 were recorded. @entity2 ( @entity2 ) was adjusted for @entity1 rates in the normal population. RESULTS: Incidence in males decreased slightly from 1.2 per 100.000 @entity0 years (PY) in 1989-2000 to 0.9 in 2001-2012. For females, incidence remained stable with 0.7 per 100.000 PY in both periods. Incidence was age dependent and highest in males in the last decades of life. Treatment before 2000 mainly consisted of chemotherapy, while after 2007 TKI use was 88%. Five-year relative survival was only 36% before the introduction of TKIs but significantly increased to79% after the introduction of TKI. CONCLUSIONS: This study gives insight in @entity3 incidence, treatment and survival in routine care in the Netherlands. Although @entity2 improved since the introduction of TKIs, there is still room for further improvement. This article is protected by copyright. All rights reserved.

title: @entity3 in The Netherlands: a Population-Based Study on Incidence, Treatment and Survival in 3,585 XXXX from 1989-2012.

answer: @entity0


abstract: OBJECTIVE: It is debatable if the strength of @entity2 -mortality association depends on age. The objective of this study was to investigate the influence of age on the @entity2 -mortality association in @entity0 and @entity0 , and to assess if adjusting for major confounding factors altered the age-dependent trend of the @entity2 -mortality association. DESIGN AND METHODS: Articles were identified by searches of PubMed through 15 August 2013. Twenty studies which reported two or more age-specific effect estimates were identified. A random-effect approach was applied to estimate pooled effect sizes for different age groups. RESULTS: There was a significant heterogeneity among studies within each age group in the effect estimates for the association between @entity2 and mortality. The pooled hazard ratio estimates decreased with increasing age from 1.59 (95% confidence interval, 1.46-1.72) for @entity0 and 1.60 (1.49-1.72) for @entity0 under 35 years to 1.11 (1.08-1.15) for @entity0 and 1.11 (1.09-1.14) for @entity0 75 years or older. On average, the effect estimate was decreased by about 10% with every 10 years increase in age. CONCLUSIONS: Adjusting for known confounding factors of smoking, pre-existing illness, @entity3 and @entity1 has little impact on the age-dependent decline trend of the @entity2 -mortality association. Therefore, the strength of the association between @entity2 and mortality weakens with increasing age.

title: Age-dependent decline of association between XXXX and mortality: A systematic review and meta-analysis.

answer: @entity2


abstract: @entity2 is a chronic inflammatory condition associated with an increased production of cytokines and exacerbated immune response. However, @entity2 subjects are susceptible to @entity4 and respond poorly to vaccines. This study evaluated the immune responses of @entity2 @entity1 and the underlying mechanisms by exploring the roles of myeloid cells. Diet-induced @entity2 (DIO) @entity1 were prepared from C57BL/6J @entity1 fed a high-calorie and high-fat diet for 12 weeks. Humoral and cellular immune responses of DIO @entity1 to a @entity5 vaccine containing the @entity5 surface antigen (HBsAg) were assessed in sera and via a lymphoproliferative assay, respectively. The effects of @entity6 (+)GR1(+) myeloid-derived suppressor cells (MDSC) and @entity6 (+)GR1(-) non-MDSC on T cell proliferation and cytokine production were compared via a cell culture system. The production of cytokines, expression of activation and exhaustion markers, and proportions of apoptotic T cells were estimated with flow cytometry. Increased T and B lymphocyte proliferation and higher interferon-y and @entity0 @entity3 factor-a levels were detected in spleen cells and liver non-parenchymal cell cultures of DIO @entity1 compared to controls (p<0.05). However, antibody to HBsAg (anti-HBs) levels and HBsAg-specific T cell proliferation were significantly lower in DIO @entity1 compared to controls (p<0.05). The addition of MDSC, but not non-MDSC, induced a decrease in HBsAg-specific T cell proliferation, lower cytokine production, decrease in T cell activation, and increase in T cell exhaustion and apoptosis (p<0.05). MDSC play an important role in mediating impaired antigen-specific immunity.

title: Diminished immune response to vaccinations in XXXX : Role of myeloid-derived suppressor and other myeloid cells.

answer: @entity2


abstract: OBJECTIVES: The study aim was to confirm the factorial structure of the short (14 item) version of the @entity3 quality of life Questionnaire (CIVIQ-14) using the Vein Consult Program (VCP) results. METHODS: The international VCP study sought to evaluate the impact of @entity1 ( @entity1 ) on health care costs and quality of life (QoL). The factorial structure of the CIVIQ-14 was evaluated using two methods: exploratory factor analysis (EFA) to calculate the probabilities of items and dimensions remaining stable and to study the dimensionality of the scale using explained variance criteria, followed by confirmatory factor analysis ( @entity2 ) to confirm the original three dimensional structure and investigate alternative models that may have arisen from the dimensionality analysis. We also used the VCP results to evaluate the psychometric properties of the questionnaire and conducted subgroup analyses on countries with validated translations. RESULTS: A total of 47,149 questionnaires from 17 countries were available in the VCP. EFA revealed both items and dimensions as 100% stable. Dimensionality analysis showed that a two factor approach could be considered. @entity2 revealed the CIVIQ-14 three dimensional structure to be acceptable while rejecting the two dimensional model. Psychometric analysis confirmed the construct validity, internal consistency, and known groups validity of the CIVIQ-14. The results of subgroup analyses were consistent with those of the primary analysis. CONCLUSIONS: @entity2 of VCP data supported the factorial structure of the CIVIQ-14. The analysis corroborates the wide use of CIVIQ-14 as a valid instrument for reporting QoL in @entity1 @entity0 .

title: Psychometric Validation of the 14 items XXXX Quality of Life Questionnaire (CIVIQ-14): Confirmatory Factor Analysis.

answer: @entity3


abstract: BACKGROUND: @entity9 and @entity4 are associated with an increased risk of @entity2 ( @entity2 ). It is unknown whether treating @entity9 with @entity8 oxidase inhibitors (XOIs), including @entity3 and @entity10 , modifies @entity2 . METHODS: We used US insurance claims data to conduct a cohort study among @entity4 @entity0 , comparing XOI initiators with non-users with @entity9 defined as serum @entity5 level >= 6.8 mg/dL. We calculated incidence rates of a composite nonfatal cardiovascular outcome that included @entity6 , coronary revascularization, @entity1 , and @entity7 . Propensity score (PS)-matched Cox proportional hazards regression compared the risk of composite cardiovascular endpoint in XOI initiators vs those with untreated @entity9 , controlling for baseline confounders. In a subgroup of @entity0 with @entity5 levels available, PS-matched Cox regression further adjusted for baseline @entity5 levels. RESULTS: There were 24,108 PS-matched pairs with a mean age of 51 years and 88% male. The incidence rate per 1000 @entity0 -years for composite @entity2 was 24.1 (95% confidence interval [CI] 22.6-26.0) in XOI initiators and 21.4 (95% CI, 19.8-23.2) in the untreated @entity9 group. The PS-matched hazard ratio for composite @entity2 was 1.16 (95% CI, 0.99-1.34) in XOI initiators vs those with untreated @entity9 . In subgroup analyses, the PS-matched hazard ratio for composite @entity2 adjusted for serum @entity5 levels was 1.10 (95% CI, 0.74-1.64) among XOI initiators. CONCLUSIONS: Among @entity0 with @entity4 , initiation of XOI was not associated with an increased or decreased cardiovascular risk compared with those with untreated @entity9 . Subgroup analyses adjusting for baseline @entity5 levels also showed no association between XOI and cardiovascular risk.

title: Effects of @entity8 oxidase inhibitors on @entity2 in @entity0 with XXXX : a cohort study.

answer: @entity4


abstract: BACKGROUND: @entity9 and @entity4 are associated with an increased risk of @entity2 ( @entity2 ). It is unknown whether treating @entity9 with @entity8 oxidase inhibitors (XOIs), including @entity3 and @entity10 , modifies @entity2 . METHODS: We used US insurance claims data to conduct a cohort study among @entity4 @entity0 , comparing XOI initiators with non-users with @entity9 defined as serum @entity5 level >= 6.8 mg/dL. We calculated incidence rates of a composite nonfatal cardiovascular outcome that included @entity6 , coronary revascularization, @entity1 , and @entity7 . Propensity score (PS)-matched Cox proportional hazards regression compared the risk of composite cardiovascular endpoint in XOI initiators vs those with untreated @entity9 , controlling for baseline confounders. In a subgroup of @entity0 with @entity5 levels available, PS-matched Cox regression further adjusted for baseline @entity5 levels. RESULTS: There were 24,108 PS-matched pairs with a mean age of 51 years and 88% male. The incidence rate per 1000 @entity0 -years for composite @entity2 was 24.1 (95% confidence interval [CI] 22.6-26.0) in XOI initiators and 21.4 (95% CI, 19.8-23.2) in the untreated @entity9 group. The PS-matched hazard ratio for composite @entity2 was 1.16 (95% CI, 0.99-1.34) in XOI initiators vs those with untreated @entity9 . In subgroup analyses, the PS-matched hazard ratio for composite @entity2 adjusted for serum @entity5 levels was 1.10 (95% CI, 0.74-1.64) among XOI initiators. CONCLUSIONS: Among @entity0 with @entity4 , initiation of XOI was not associated with an increased or decreased cardiovascular risk compared with those with untreated @entity9 . Subgroup analyses adjusting for baseline @entity5 levels also showed no association between XOI and cardiovascular risk.

title: Effects of XXXX oxidase inhibitors on @entity2 in @entity0 with @entity4 : a cohort study.

answer: @entity8


abstract: BACKGROUND: @entity9 and @entity4 are associated with an increased risk of @entity2 ( @entity2 ). It is unknown whether treating @entity9 with @entity8 oxidase inhibitors (XOIs), including @entity3 and @entity10 , modifies @entity2 . METHODS: We used US insurance claims data to conduct a cohort study among @entity4 @entity0 , comparing XOI initiators with non-users with @entity9 defined as serum @entity5 level >= 6.8 mg/dL. We calculated incidence rates of a composite nonfatal cardiovascular outcome that included @entity6 , coronary revascularization, @entity1 , and @entity7 . Propensity score (PS)-matched Cox proportional hazards regression compared the risk of composite cardiovascular endpoint in XOI initiators vs those with untreated @entity9 , controlling for baseline confounders. In a subgroup of @entity0 with @entity5 levels available, PS-matched Cox regression further adjusted for baseline @entity5 levels. RESULTS: There were 24,108 PS-matched pairs with a mean age of 51 years and 88% male. The incidence rate per 1000 @entity0 -years for composite @entity2 was 24.1 (95% confidence interval [CI] 22.6-26.0) in XOI initiators and 21.4 (95% CI, 19.8-23.2) in the untreated @entity9 group. The PS-matched hazard ratio for composite @entity2 was 1.16 (95% CI, 0.99-1.34) in XOI initiators vs those with untreated @entity9 . In subgroup analyses, the PS-matched hazard ratio for composite @entity2 adjusted for serum @entity5 levels was 1.10 (95% CI, 0.74-1.64) among XOI initiators. CONCLUSIONS: Among @entity0 with @entity4 , initiation of XOI was not associated with an increased or decreased cardiovascular risk compared with those with untreated @entity9 . Subgroup analyses adjusting for baseline @entity5 levels also showed no association between XOI and cardiovascular risk.

title: Effects of @entity8 oxidase inhibitors on XXXX in @entity0 with @entity4 : a cohort study.

answer: @entity2


abstract: BACKGROUND: @entity9 and @entity4 are associated with an increased risk of @entity2 ( @entity2 ). It is unknown whether treating @entity9 with @entity8 oxidase inhibitors (XOIs), including @entity3 and @entity10 , modifies @entity2 . METHODS: We used US insurance claims data to conduct a cohort study among @entity4 @entity0 , comparing XOI initiators with non-users with @entity9 defined as serum @entity5 level >= 6.8 mg/dL. We calculated incidence rates of a composite nonfatal cardiovascular outcome that included @entity6 , coronary revascularization, @entity1 , and @entity7 . Propensity score (PS)-matched Cox proportional hazards regression compared the risk of composite cardiovascular endpoint in XOI initiators vs those with untreated @entity9 , controlling for baseline confounders. In a subgroup of @entity0 with @entity5 levels available, PS-matched Cox regression further adjusted for baseline @entity5 levels. RESULTS: There were 24,108 PS-matched pairs with a mean age of 51 years and 88% male. The incidence rate per 1000 @entity0 -years for composite @entity2 was 24.1 (95% confidence interval [CI] 22.6-26.0) in XOI initiators and 21.4 (95% CI, 19.8-23.2) in the untreated @entity9 group. The PS-matched hazard ratio for composite @entity2 was 1.16 (95% CI, 0.99-1.34) in XOI initiators vs those with untreated @entity9 . In subgroup analyses, the PS-matched hazard ratio for composite @entity2 adjusted for serum @entity5 levels was 1.10 (95% CI, 0.74-1.64) among XOI initiators. CONCLUSIONS: Among @entity0 with @entity4 , initiation of XOI was not associated with an increased or decreased cardiovascular risk compared with those with untreated @entity9 . Subgroup analyses adjusting for baseline @entity5 levels also showed no association between XOI and cardiovascular risk.

title: Effects of @entity8 oxidase inhibitors on @entity2 in XXXX with @entity4 : a cohort study.

answer: @entity0


abstract: PURPOSE: There is controversy surrounding the growth outcomes of treatment with @entity4 agonist ( @entity5 ) in central precocious puberty (CPP). We analyzed height preservation after treatment with @entity5 with and without @entity2 ( @entity2 ) in @entity0 with CPP. METHODS: We reviewed the medical records of 82 @entity0 with idiopathic CPP who had been treated with @entity5 at Severance @entity0 's Hospital from 2004 to 2014. We assessed the changes in height standard deviation score ( @entity1 ) for bone age (BA), and compared @entity6 ( @entity6 ) with midparental height ( @entity7 ) and predicted @entity6 ( @entity3 ) during treatment in groups received @entity5 alone (n=59) or @entity5 plus @entity2 (n=23). RESULTS: In the @entity5 alone group, the height SDS for BA was increased during treatment. @entity6 (160.4  4.23 cm) was significantly higher than the initial @entity3 (156.6  3.96 cm) (P<0.001), and it was similar to the @entity7 (159.9  3.52 cm). In the @entity5 plus @entity2 group, the height SDS for BA was also increased during treatment. @entity6 (159.3  5.33 cm) was also higher than the initial @entity3 (154.6  2.55 cm) (P<0.001), which was similar to the @entity7 (158.1  3.31 cm). Height gain was slightly higher than that in the @entity5 alone group, however it statistically showed no significant correlation with @entity2 treatment. CONCLUSION: In CPP @entity0 treated with @entity5 , the height SDS for BA was increased, and the @entity6 was higher than the initial @entity3 . Combined @entity2 treatment showed a limited increase in height gain.

title: Adult height in @entity0 with central precocious puberty treated with @entity4 agonist with or without XXXX .

answer: @entity2


abstract: PURPOSE: There is controversy surrounding the growth outcomes of treatment with @entity4 agonist ( @entity5 ) in central precocious puberty (CPP). We analyzed height preservation after treatment with @entity5 with and without @entity2 ( @entity2 ) in @entity0 with CPP. METHODS: We reviewed the medical records of 82 @entity0 with idiopathic CPP who had been treated with @entity5 at Severance @entity0 's Hospital from 2004 to 2014. We assessed the changes in height standard deviation score ( @entity1 ) for bone age (BA), and compared @entity6 ( @entity6 ) with midparental height ( @entity7 ) and predicted @entity6 ( @entity3 ) during treatment in groups received @entity5 alone (n=59) or @entity5 plus @entity2 (n=23). RESULTS: In the @entity5 alone group, the height SDS for BA was increased during treatment. @entity6 (160.4  4.23 cm) was significantly higher than the initial @entity3 (156.6  3.96 cm) (P<0.001), and it was similar to the @entity7 (159.9  3.52 cm). In the @entity5 plus @entity2 group, the height SDS for BA was also increased during treatment. @entity6 (159.3  5.33 cm) was also higher than the initial @entity3 (154.6  2.55 cm) (P<0.001), which was similar to the @entity7 (158.1  3.31 cm). Height gain was slightly higher than that in the @entity5 alone group, however it statistically showed no significant correlation with @entity2 treatment. CONCLUSION: In CPP @entity0 treated with @entity5 , the height SDS for BA was increased, and the @entity6 was higher than the initial @entity3 . Combined @entity2 treatment showed a limited increase in height gain.

title: Adult height in @entity0 with central precocious puberty treated with XXXX agonist with or without @entity2 .

answer: @entity4


abstract: PURPOSE: There is controversy surrounding the growth outcomes of treatment with @entity4 agonist ( @entity5 ) in central precocious puberty (CPP). We analyzed height preservation after treatment with @entity5 with and without @entity2 ( @entity2 ) in @entity0 with CPP. METHODS: We reviewed the medical records of 82 @entity0 with idiopathic CPP who had been treated with @entity5 at Severance @entity0 's Hospital from 2004 to 2014. We assessed the changes in height standard deviation score ( @entity1 ) for bone age (BA), and compared @entity6 ( @entity6 ) with midparental height ( @entity7 ) and predicted @entity6 ( @entity3 ) during treatment in groups received @entity5 alone (n=59) or @entity5 plus @entity2 (n=23). RESULTS: In the @entity5 alone group, the height SDS for BA was increased during treatment. @entity6 (160.4  4.23 cm) was significantly higher than the initial @entity3 (156.6  3.96 cm) (P<0.001), and it was similar to the @entity7 (159.9  3.52 cm). In the @entity5 plus @entity2 group, the height SDS for BA was also increased during treatment. @entity6 (159.3  5.33 cm) was also higher than the initial @entity3 (154.6  2.55 cm) (P<0.001), which was similar to the @entity7 (158.1  3.31 cm). Height gain was slightly higher than that in the @entity5 alone group, however it statistically showed no significant correlation with @entity2 treatment. CONCLUSION: In CPP @entity0 treated with @entity5 , the height SDS for BA was increased, and the @entity6 was higher than the initial @entity3 . Combined @entity2 treatment showed a limited increase in height gain.

title: Adult height in XXXX with central precocious puberty treated with @entity4 agonist with or without @entity2 .

answer: @entity0


abstract: The effects of simulated microgravity on the static and dynamic properties of large arteries are still mostly unknown. The present study evaluated, using an integrated vascular approach, changes in structure and function of the common carotid and femoral arteries (CCA and @entity1 ) after prolonged head-down tilt bed rest (HDTBR). Ten healthy @entity0 were enrolled in a 5-week HDTBR study endorsed by the Italian Space Agency (ASI). Arterial geometry, flow, stiffness, and shear rate were evaluated by ultrasound. Local carotid pulse pressure and wave reflection were studied by applanation tonometry. After five weeks of HDTBR, @entity1 showed a decrease in lumen diameter without significant changes in wall thickness (IMT), resulting in an inward remodeling. Local carotid pulse pressure decreased and carotid-to-brachial pressure amplification increased. The ratio of systolic-to-diastolic volumetric flow in @entity1 decreased, whereas in CCA it tended to increase. Indices of arterial stiffness and shear rate did not change during HDTBR, either in CCA or @entity1 . In summary, prolonged HDTBR has a different impact on CCA and @entity1 structure and flow, probably depending on the characteristics of the vascular bed perfused.

title: Large Artery Remodeling and Dynamics following Simulated Microgravity by Prolonged Head-Down Tilt Bed Rest in XXXX .

answer: @entity0


abstract: PURPOSE:: Advances in video-assisted thoracoscopic surgery have allowed endoscopic surgical sympathicotomy to become a viable safe therapy for upper limb @entity1 . We evaluated if and how this procedure improves the quality of life in @entity0 after a mean follow-up of 9.5 years. METHODS:: Between 1995 and 2013, the senior author performed 1440 upper dorsal sympathicotomies in 720 @entity0 . Questionnaires were submitted to randomized @entity0 , both to evaluate the durability of the results and to assess their quality of life after surgery. RESULTS:: In 46 @entity0 , anatomical distinctive features obscured the sympathetic chain, precluding partial or total completion of the procedure. The other 674 @entity0 reported complete relief of symptoms. A mean follow-up of 9.5 years (range, 2 to 17 y) was carried out on 450 @entity0 : 6 recurrences have been observed, severe @entity2 was reported in 3 @entity0 , and 441 @entity0 were satisfied with nothing to complain. Furthermore, when comparing presurgery and postsurgery results, a statistically significant difference between most of @entity0 answers came out (P=0.001). CONCLUSION:: According to the data obtained, the procedure we described significantly improves the quality of life of treated @entity0 , also proving the durability of this procedure. DISCUSSION:: Minimally invasive endoscopic transthoracic sympathicotomy has proven to be an effective and durable surgical treatment for severe primary @entity1 .

title: Video-assisted Thoracic Sympathicotomy for the Treatment of XXXX : A 17-Year Experience.

answer: @entity1


abstract: UNASSIGNED: Pro-inflammatory cytokine-induced chondrocyte apoptosis is a primary cause of cartilage destruction in the progression of @entity2 ( @entity2 ). Advanced oxidation protein products (AOPPs), a novel pro-inflammatory mediator, have been confirmed to accumulate in @entity0 with @entity2 . However, the effect of AOPPs accumulation on chondrocyte apoptosis and the associated cellular mechanisms remains unclear. The present study demonstrated that the plasma formation of AOPPs was enhanced in @entity2 @entity1 compared with normal. Then, chondrocyte were treated with AOPPs-modified rat serum albumin (AOPPs-RSA) in vitro. Exposure of chondrocyte to AOPPs activated @entity3 ( @entity3 ) oxidase and increased expression of @entity3 oxidase subunits, which was mediated by @entity6 ( @entity6 ), but not scavenger receptor @entity5 . Moreover, AOPPs challenge triggered @entity3 oxidase-dependent ROS generation which induced @entity4 and endoplasmic reticulum stress resulted in activation of caspase family that eventually lead to apoptosis. Lastly, blockade of @entity6 , instead of @entity5 , largely attenuated these signals. Our study demonstrated first time that AOPPs induce chondrocyte apoptosis via @entity6 -mediated and redox-dependent intrinsic apoptosis pathway in vitro. These data implicates that AOPPs may represent a novel pathogenic factor that contributes to @entity2 progression. Targeting AOPPs-triggered cellular mechanisms might emerge as a promising therapeutic option for @entity0 with @entity2 .

title: Advanced oxidation protein products induce chondrocyte apoptosis via XXXX -mediated, redox-dependent intrinsic apoptosis pathway.

answer: @entity6


abstract: UNASSIGNED: Our previous RNA-sequencing analysis of the @entity2 cochlear genes identified multiple biological processes and molecular pathways in the cochlear response to acoustic overstimulation. However, the biological processes and molecular pathways that are common to other species have not been documented. The identification of these common stress processes is pivotal for a better understanding of the essential response of the cochlea to @entity3 . Here, we compared the RNA-sequencing data collected from @entity0 and @entity2 that sustained a similar, but not identical, @entity3 . The transcriptome analysis of cochlear genes identified the differentially expressed genes in the @entity0 and @entity2 samples. Bioinformatics analysis revealed a marked similarity in the changes in the biological processes between the two species, although the differentially expressed genes did not overlap well. The common processes associated with the differentially expressed genes are primarily associated with @entity4 and @entity1 , which include the immune response, response to wounding, the defense response, @entity5 and inflammatory responses. Moreover, analysis of the molecular pathways showed considerable overlap between the two species. The common pathways include cytokine-cytokine receptor interactions, the chemokine signaling pathway, the Toll-like receptor signaling pathway, and the NOD-like receptor signaling pathway. Further analysis of the transcriptional regulators revealed common upstream regulators of the differentially expressed genes, and these upstream regulators are also functionally related to the immune and inflammatory responses. These results suggest that the immune and inflammatory responses are the essential responses to acoustic overstimulation in the cochlea.

title: Immune defense is the primary function associated with the differentially expressed genes in the cochlea following acoustic XXXX .

answer: @entity3


abstract: PURPOSE: To compare the age-based cost-effectiveness of @entity1 ( @entity1 ), unicompartmental knee arthroplasty (UKA), and high tibial osteotomy (HTO) for the treatment of @entity2 ( @entity2 ). METHODS: A Markov model was used to simulate theoretical cohorts of @entity0 40, 50, 60, and 70  years of age undergoing primary @entity1 , UKA, or HTO. Costs and outcomes associated with initial and subsequent interventions were estimated by following these virtual cohorts over a 10-year period. Revision and mortality rates, costs, and functional outcome data were estimated from a systematic review of the literature. Probabilistic analysis was conducted to accommodate these parameters' inherent uncertainty, and both discrete and probabilistic sensitivity analyses were utilized to assess the robustness of the model's outputs to changes in key variables. RESULTS: HTO was most likely to be cost-effective in cohorts under 60, and UKA most likely in those 60 and over. Probabilistic results did not indicate one intervention to be significantly more cost-effective than another. The model was exquisitely sensitive to changes in utility (functional outcome), somewhat sensitive to changes in cost, and least sensitive to changes in 10-year revision risk. CONCLUSIONS: HTO may be the most cost-effective option when treating @entity2 in younger @entity0 , while UKA may be preferred in older @entity0 . Functional utility is the primary driver of the cost-effectiveness of these interventions. For the clinician, this study supports HTO as a competitive treatment option in young @entity0 populations. It also validates each one of the three interventions considered as potentially optimal, depending heavily on @entity0 preferences and functional utility derived over time.

title: Medial compartment knee osteoarthritis: age-stratified cost-effectiveness of XXXX , unicompartmental knee arthroplasty, and high tibial osteotomy.

answer: @entity1


abstract: PURPOSE: The incidence and etiology of @entity4 with @entity2 (EWF) in @entity0 is unknown. We analyzed a national database to define the epidemiology and diagnoses associated with this condition. METHODS: Discharge data from the Kids' Inpatient Database were reviewed for EWF (ICD-9 diagnosis code 510.0) in @entity0  <=18  years from 2000 to 2012. @entity0 characteristics, institutional data, and accompanying conditions were evaluated. Weighted national estimates were calculated and incidence compared across years (2000, 2003, 2006, 2009) using the Rao-Scott Chi Square. RESULTS: From 2000 to 2012, 908 @entity0 were hospitalized with EWF. Age distribution was bimodal. Common primary diagnoses related to the hospitalization were @entity1 / @entity3 (31.2  %) and EWF (19.3  %). Manipulation of the pleural space (e.g. decortication, drainage) comprised 45.0  % of procedures. Incidence rates of EWF increased (Rao Scott Adjusted Chi Square: 16.13, p  <  0.01) over the study period. Although not statistically significant, median length of stay and age of diagnosis decreased and increased, respectively. CONCLUSION: This first, national pediatric EWF study reveals rising incidence during the years 2000-2009. Despite limitations in ICD-9 coding, concomitant primary diagnoses and procedures suggest bronchopleural fistulae likely represent the vast majority of cases in this cohort. Multi-institutional studies are needed to confirm etiology and characterize outcome of EWF.

title: The rising incidence of @entity4 with XXXX .

answer: @entity2


abstract: PURPOSE: The incidence and etiology of @entity4 with @entity2 (EWF) in @entity0 is unknown. We analyzed a national database to define the epidemiology and diagnoses associated with this condition. METHODS: Discharge data from the Kids' Inpatient Database were reviewed for EWF (ICD-9 diagnosis code 510.0) in @entity0  <=18  years from 2000 to 2012. @entity0 characteristics, institutional data, and accompanying conditions were evaluated. Weighted national estimates were calculated and incidence compared across years (2000, 2003, 2006, 2009) using the Rao-Scott Chi Square. RESULTS: From 2000 to 2012, 908 @entity0 were hospitalized with EWF. Age distribution was bimodal. Common primary diagnoses related to the hospitalization were @entity1 / @entity3 (31.2  %) and EWF (19.3  %). Manipulation of the pleural space (e.g. decortication, drainage) comprised 45.0  % of procedures. Incidence rates of EWF increased (Rao Scott Adjusted Chi Square: 16.13, p  <  0.01) over the study period. Although not statistically significant, median length of stay and age of diagnosis decreased and increased, respectively. CONCLUSION: This first, national pediatric EWF study reveals rising incidence during the years 2000-2009. Despite limitations in ICD-9 coding, concomitant primary diagnoses and procedures suggest bronchopleural fistulae likely represent the vast majority of cases in this cohort. Multi-institutional studies are needed to confirm etiology and characterize outcome of EWF.

title: The rising incidence of XXXX with @entity2 .

answer: @entity4


abstract: @entity5 ( @entity5 ) is one of the severe complications of @entity2 ( @entity2 ) and total knee arthroplasty (TKA). The incidence of @entity5 could be reduced if preventive antithrombotic medicines are used; however, the incidence of @entity1 may increase. @entity7 is a factor Xa inhibitor that prevents @entity5 after @entity2 or TKA. This study is designed to confirm the efficacy and safety of @entity7 in Taiwan. This is a retrospective database study based on the data of 6996 @entity0 provided by the Taiwan National Health Insurance Research Database from 2008 to 2012. The data included the number of prescription, the cost of prescription, and case number for @entity0 treated with antithrombotic agents for the prevention or @entity6 (including @entity2 , TKA, partial hip arthroplasty, revision @entity2 and TKA), and the incidence of @entity3 and @entity1 from year 2008 to 2012. The overall postoperative @entity5 rate was 0.49%. Compared with other antithrombotic drugs, @entity7 and @entity8 analogs can reduce the percentage of @entity3 . We also found that the expenditure and hospitalization was less in the @entity7 group than in the @entity8 analogs group. Because some benefits of @entity7 were found in our study, further cost-effective and drug safety studies are warranted. It is important to consider the cost-effective principle for the use of antithrombotic drugs in preventing @entity4 after @entity6 .

title: XXXX in preventing @entity5 after arthroplastic surgery in Taiwan.

answer: @entity7


abstract: @entity5 ( @entity5 ) is one of the severe complications of @entity2 ( @entity2 ) and total knee arthroplasty (TKA). The incidence of @entity5 could be reduced if preventive antithrombotic medicines are used; however, the incidence of @entity1 may increase. @entity7 is a factor Xa inhibitor that prevents @entity5 after @entity2 or TKA. This study is designed to confirm the efficacy and safety of @entity7 in Taiwan. This is a retrospective database study based on the data of 6996 @entity0 provided by the Taiwan National Health Insurance Research Database from 2008 to 2012. The data included the number of prescription, the cost of prescription, and case number for @entity0 treated with antithrombotic agents for the prevention or @entity6 (including @entity2 , TKA, partial hip arthroplasty, revision @entity2 and TKA), and the incidence of @entity3 and @entity1 from year 2008 to 2012. The overall postoperative @entity5 rate was 0.49%. Compared with other antithrombotic drugs, @entity7 and @entity8 analogs can reduce the percentage of @entity3 . We also found that the expenditure and hospitalization was less in the @entity7 group than in the @entity8 analogs group. Because some benefits of @entity7 were found in our study, further cost-effective and drug safety studies are warranted. It is important to consider the cost-effective principle for the use of antithrombotic drugs in preventing @entity4 after @entity6 .

title: @entity7 in preventing XXXX after arthroplastic surgery in Taiwan.

answer: @entity5


abstract: OBJECTIVES: @entity4 ( @entity4 ) are the most common lesions in the extramedullary intradural compartment. Complex and large lesions may pose technical difficulties for the operating surgeons. We discuss the management of @entity4 and technical issues including surgical approaches, spinal fixation, and dural handling with the goal of achieving good clinical outcomes while minimizing the risk of complications. We also propose a new classification for @entity4 to guide surgical treatment of these @entity1 . METHODS: A retrospective analysis was performed of 61 @entity0 who underwent surgery for @entity4 during the period 1995-2012. The posterior approach was used for removal of most @entity1 (n  = 53). Lesions having a substantial extraforaminal component were accessed from the anterior or lateral approach or a combined approach. Concomitant spinal fixation and fusion was performed in 7 @entity0 . RESULTS: Most of the @entity0 (n  = 53) had clinical improvement; clinical status was the same in 4 @entity0 and worse in the remaining 4 @entity0 . One or more complications developed in 18 @entity0 (29.5%). Recurrence was the most common complication (n  = 7). @entity2 occurred in 2 @entity0 with @entity3 12 and 8 months, respectively, after surgical resection. CONCLUSIONS: Lesions with large extraforaminal extension pose technical difficulty. Spinal fixation with fusion should be supplemented whenever necessary. Complications related to dura mater may be associated with significant morbidity, and all possible efforts should be made to prevent them.

title: Surgical Strategies in the Management of XXXX .

answer: @entity4


abstract: OBJECTIVE: To review and appraise common vasopressor drugs used to treat @entity2 -induced @entity4 in volume replete animals. DATA SOURCES: @entity0 and animal publications were searched using PubMed without time limits and the following keywords were used: "vasopressor," " @entity2 ," " @entity7 ," " @entity6 ," " @entity8 ," and "vasopressin." @entity0 DATA SYNTHESIS: The choice of vasopressor drug is unlikely to have a marked impact on outcome, but the incidence of adverse events (eg, @entity5 ) varies greatly between the various treatment options. In agreement with the 2012 Cochrane Database consensus, @entity7 is the first-choice vasopressor to maintain a mean arterial pressure >= 65 mm Hg. If an additional agent is required, epinephrine should be administered. Low-dose vasopressin can be added to @entity7 to either increase the arterial blood pressure to the target goal value or decrease the @entity7 dose, but should not be used as the initial vasopressor. @entity6 is not recommended except in highly selected circumstances. VETERINARY DATA SYNTHESIS: There is insufficient evidence to make definitive conclusions regarding the treatment of naturally occurring @entity2 , but clinical studies are underway to provide further data. CONCLUSIONS: The treatment of @entity4 in @entity0 or animals with @entity2 is challenging and vasopressor therapy is associated with a variety of adverse effects. Further research is warranted in @entity1 and @entity3 to establish evidence-based guidelines.

title: Controversies regarding choice of vasopressor therapy for management of XXXX in animals.

answer: @entity2


abstract: A retrospective study interesting 582 anatomoclinical cases of @entity3 was realised in two anatomo-pathological services of Tunis from 1970 to 1985. The average age of @entity0 is 55 years old, with extensive ranges from 17 to 85 years old. The authors point out significative male predominance 64.6% of cases. The ulcered form is the most frequent, about 3.8% of macroscopic aspect cases. Among these last, the authors find 26.7% of ulcerating and polypoid form with invasive characteristics, and 18.83% of @entity6 . The pyloric area localisation is the most frequent, 68% of cases. Diffuse @entity2 are observed in 8.47% of cases and numerous stomach localisation in 0.82% of cases. 84% of histological aspect are represented by @entity4 , the most frequent of them (35%) is well differentiated type, then the poorly differentiated (20%) and atypic form (19.75%). Frequency of @entity5 reaches 14.7%, the first is the centroblastic form, then lymphoblastic and lymphoplasmocytic forms. Concerning evolution, @entity3 is an infiltrative @entity2 : serosal surface is attempted in 69.5% of cases, and during the first chirurgical act half cases show lymph nodes @entity1 .

title: [ XXXX of the stomach: apropos of 583 anatomo-clinical cases].

answer: @entity2


abstract: BACKGROUND/AIMS: Several limiting factors for @entity0 health and performance in microgravity have been clearly identified arising from the immune system, and substantial research activities are required in order to provide the basic information for appropriate integrated risk management. The gravity-sensitive nature of cells of the immune system renders them an ideal biological model in search for general gravity-sensitive mechanisms and to understand how the architecture and function of @entity0 cells is related to the gravitational force and therefore adapted to life on Earth. METHODS: We investigated the influence of altered gravity in parabolic flight and 2D clinostat experiments on key proteins of activation and signaling in primary T lymphocytes. We quantified components of the signaling cascade 1.) in non-activated T lymphocytes to assess the "basal status" of the cascade and 2.) in the process of activation to assess the signal transduction. RESULTS: We found a rapid decrease of CD3 and @entity1 surface expression and reduced p-LAT after 20 seconds of altered gravity in non-activated primary T lymphocytes during parabolic flight. Furthermore, we observed decreased CD3 surface expression, reduced @entity2 abundance and increased histone H3-acetylation in activated T lymphocytes after 5 minutes of clinorotation and a transient downregulation of CD3 and stable downregulation of @entity1 during 60 minutes of clinorotation. CONCLUSION: CD3 and @entity1 are downregulated in primary T lymphocytes in altered gravity. We assume that a gravity condition around 1g is required for the expression of key surface receptors and appropriate regulation of signal molecules in T lymphocytes.    2015 S. Karger AG, Basel.

title: Signal transduction in primary XXXX T lymphocytes in altered gravity during parabolic flight and clinostat experiments.

answer: @entity0


abstract: UNASSIGNED: @entity2 caused by house dust mite (HDM) is becoming a public health problem. Specific immunotherapy is considered to be the only curative treatment, but it is always associated with IgE-mediated side effects in the therapy process. A few studies showed that the disruption of allergen IgE epitopes could reduce IgE reactivity and thus reduce allergenic activity. In this study, a hypoallergenic derivative of the major HDM allergen Der p2 was constructed by genetic engineering. This derivative was confirmed to have a considerably reduced IgE reactivity compared with Der p2. For its application in vivo, recombinant @entity5 (LL-DM) was engineered to deliver the Der p2 derivative to the intestinal mucosal surface. Oral administration of LL-DM significantly alleviated Der p2-induced @entity1 , as shown by reduced inflammatory infiltration and a reduction in Th2 cytokines in bronchoalveolar lavage. This protective effect was associated with an up-regulation of specific @entity6 and a decrease in @entity3 level in the spleen which may affect specific IgE response. Moreover, the levels of regulatory T cells in the mesenteric lymph nodes and spleen were markedly increased in @entity0 fed with LL-DM, suggesting that LL-DM can inhibit allergic responses via the induction of regulatory T cell. Our results indicate that the Der p2 derivative is a promising therapeutic molecule for specific immunotherapy and recombinant @entity4 bacteria could be developed as a promising treatment or prevention strategy for @entity2 .

title: Suppression of dust mite allergy by mucosal delivery of a hypoallergenic derivative in a XXXX model.

answer: @entity0


abstract: The pathology and enzymology of the intestinal mucosae of @entity4 dosed daily with 2500 @entity9 larvae and killed at five, nine or 14 weeks were compared with worm-free animals. The proximal small intestines of the infected @entity4 exhibited extensive @entity0 at five and nine weeks, but only isolated lesions were found at 14 weeks. Activities of the brush border enzymes alkaline phosphatase, @entity3 amino-peptidase, maltase and @entity10 dipeptidase were all significantly depleted during @entity2 , although the magnitude, time of onset and duration of the individual enzyme responses varied. Mucosal activities of the pancreatic enzymes, trypsin and to a lesser extent chymotrypsin were also markedly decreased particularly during the first nine weeks of @entity2 . Specific acetylcholinesterase activity was significantly increased throughout the study, maximal levels being observed at five weeks. In contrast 'pseudo'-cholinesterase levels were consistently within the control range. During the early stages of @entity2 (five weeks) @entity7 - @entity8 transaminase activity was significantly decreased, while aldolase and @entity6 phosphokinase levels were significantly elevated. At nine weeks low @entity7 - @entity8 transaminase activities were again detected and @entity5 dehydrogenase activity was also markedly reduced. At 14 weeks the mean activities of all four enzymes were within the normal range as were @entity1 dismutase levels throughout. Significant correlations were found between alkaline phosphatase, trypsin, chymotrypsin, aldolase and @entity7 - @entity8 transaminase activities and the degree of @entity0 within the individual @entity4 .

title: Changes in the intestinal enzyme activity of XXXX during @entity2 with @entity9 .

answer: @entity4


abstract: The pathology and enzymology of the intestinal mucosae of @entity4 dosed daily with 2500 @entity9 larvae and killed at five, nine or 14 weeks were compared with worm-free animals. The proximal small intestines of the infected @entity4 exhibited extensive @entity0 at five and nine weeks, but only isolated lesions were found at 14 weeks. Activities of the brush border enzymes alkaline phosphatase, @entity3 amino-peptidase, maltase and @entity10 dipeptidase were all significantly depleted during @entity2 , although the magnitude, time of onset and duration of the individual enzyme responses varied. Mucosal activities of the pancreatic enzymes, trypsin and to a lesser extent chymotrypsin were also markedly decreased particularly during the first nine weeks of @entity2 . Specific acetylcholinesterase activity was significantly increased throughout the study, maximal levels being observed at five weeks. In contrast 'pseudo'-cholinesterase levels were consistently within the control range. During the early stages of @entity2 (five weeks) @entity7 - @entity8 transaminase activity was significantly decreased, while aldolase and @entity6 phosphokinase levels were significantly elevated. At nine weeks low @entity7 - @entity8 transaminase activities were again detected and @entity5 dehydrogenase activity was also markedly reduced. At 14 weeks the mean activities of all four enzymes were within the normal range as were @entity1 dismutase levels throughout. Significant correlations were found between alkaline phosphatase, trypsin, chymotrypsin, aldolase and @entity7 - @entity8 transaminase activities and the degree of @entity0 within the individual @entity4 .

title: Changes in the intestinal enzyme activity of @entity4 during @entity2 with XXXX .

answer: @entity9


abstract: The pathology and enzymology of the intestinal mucosae of @entity4 dosed daily with 2500 @entity9 larvae and killed at five, nine or 14 weeks were compared with worm-free animals. The proximal small intestines of the infected @entity4 exhibited extensive @entity0 at five and nine weeks, but only isolated lesions were found at 14 weeks. Activities of the brush border enzymes alkaline phosphatase, @entity3 amino-peptidase, maltase and @entity10 dipeptidase were all significantly depleted during @entity2 , although the magnitude, time of onset and duration of the individual enzyme responses varied. Mucosal activities of the pancreatic enzymes, trypsin and to a lesser extent chymotrypsin were also markedly decreased particularly during the first nine weeks of @entity2 . Specific acetylcholinesterase activity was significantly increased throughout the study, maximal levels being observed at five weeks. In contrast 'pseudo'-cholinesterase levels were consistently within the control range. During the early stages of @entity2 (five weeks) @entity7 - @entity8 transaminase activity was significantly decreased, while aldolase and @entity6 phosphokinase levels were significantly elevated. At nine weeks low @entity7 - @entity8 transaminase activities were again detected and @entity5 dehydrogenase activity was also markedly reduced. At 14 weeks the mean activities of all four enzymes were within the normal range as were @entity1 dismutase levels throughout. Significant correlations were found between alkaline phosphatase, trypsin, chymotrypsin, aldolase and @entity7 - @entity8 transaminase activities and the degree of @entity0 within the individual @entity4 .

title: Changes in the intestinal enzyme activity of @entity4 during XXXX with @entity9 .

answer: @entity2


abstract: PURPOSE: To compare pregnancy outcome in @entity0 with normal oocyte reserve according to whether they received conventional or mild follicle stimulating hormone (FSH) controlled @entity1 (COH) further stratified by age. MATERIALS AND METHODS: A ten-year retrospective study including all cycles (even multiple in given @entity0 ) was performed. Mild stimulation including all cycles initiated and continued with 150 IU FSH or less from early follicular phase. Everything else was considered conventional stimulation. Mild stimulation included natural cycles or those with just a boost of 75 IU FSH from the mid to late follicular phase. Only @entity0 with normal oocyte reserve were selected--serum FSH < 12 mIU/mL and serum E2 < 50 pg/mL. Live delivered pregnancy rates within three age groups ( <= 35, 36-39, and 40-42 years) were compared per embryo transfer and per embryo retrieval, i.e., the percentage of @entity0 having a live baby without proceeding to another IVF-ET cycle. Also compared were the average number of babies born from one retrieval. RESULTS: For aged  <= 35 there were no differences in pregnancy rates per transfer but a trend for higher pregnancy rates per retrieval with conventional stimulation. For all other age groups both pregnancy rates per transfer and retrieval were significantly higher with conventional stimulation. This was reflected with a higher average number of babies born per retrieval with conventional. CONCLUSIONS: For @entity0 with normal oocyte reserve in general, there is no advantage of mild vs. conventional COH other than cost saving. Of course there are exceptions, e.g., @entity1 with conventional COH.

title: The effect of conventional vs. mild XXXX on the total number of live babies born from a given oocyte retrieval.

answer: @entity1


abstract: @entity3 is the leading cause of @entity2 in @entity0 and third leading cause of @entity4 in @entity0 . The prognosis worsens when @entity2 metastasizes to other organs. Thus, there is an urgent need to develop biomarkers for the early diagnosis of @entity1 as well as @entity2 development. Mass spectrometry-based technologies have been applied to the discovery of protein biomarkers, especially in the field of @entity2 . These results have identified numerous candidate protein biomarkers. Unfortunately, only a few are currently being applied in clinical diagnostics. Recent advances in proteomic technology such as selected/multiple reaction monitoring (SRM/MRM) facilitated the detection and quantitation of specific proteins in complex samples without the need for antibodies. We performed a quantitative proteomic analysis of membrane proteins extracted from @entity3 tissues using the iTRAQ shotgun method to discover biomarker candidates, and then extensively validated the biomarker candidate proteins by SRM/MRM. A total of 5,566 proteins were identified in tissue samples obtained from @entity5 and @entity2 with and without @entity1 . Differences were observed in the expression of about 400 proteins. Among them, 105 biomarker candidates which were predicted to be membrane proteins and extracellular proteins by gene ontology analysis were quantitated using SRM/MRM. As a result, we could confirm differences in the expressions of 69 of these proteins using the same set of @entity0 samples as discovery experiments, and this was subsequently verified in an independent set of samples. Significant differences were observed in the expression of 44 of these proteins. Moreover, some of the biomarker candidates were detected and quantitated in the serum of @entity3 @entity0 . These biomarker candidates are promising diagnostic tools on investigating the development and progression of @entity3 .

title: [Biomarker Discovery of XXXX Using Membrane Proteins Extracted from Cancer Tissues].

answer: @entity3


abstract: UNASSIGNED: Purpose: Autophagy plays a crucial role in cellular response to ionizing radiation, but it is unclear whether autophagy can modulate radiation-induced bystander effect (RIBE). Here, we investigated the relationship between bystander damage and autophagy in @entity0 @entity2 cells of HepG2. Materials and methods: HepG2 cells were treated with conditioned medium (CM) collected from 3 Gy y-rays irradiated @entity2 HepG2 cells for 4, 12, or 24 h, followed by the measurement of @entity4 ( @entity4 ), intracellular reactive @entity1 species (ROS), mitochondrial membrane potential (MMP), and protein expressions of @entity6 and @entity5 in the bystander HepG2 cells. In some experiments, the bystander HepG2 cells were respectively transfected with @entity6 small interfering RNA (siRNA), @entity5 siRNA or treated with 1% @entity3 ( @entity3 ). Results: Additional @entity4 and mitochondrial dysfunction coupled with ROS were induced in the bystander cells. The expressions of protein markers of autophagy, @entity6 -II/ @entity6 -I and @entity5 , increased in the bystander cells. The inductions of bystander @entity4 and overexpressions of @entity6 and @entity5 were significantly diminished by @entity3 . However, when the bystander cells were transfected with @entity6 siRNA or @entity5 siRNA, the yield of bystander @entity4 was significantly enhanced. Conclusion: The elevated ROS have bi-functions in balancing the bystander effects. One is to cause @entity4 and the other is to induce protective autophagy.

title: Role of ROS-mediated autophagy in radiation-induced bystander effect of XXXX cells.

answer: @entity2


abstract: BACKGROUND AND PURPOSE: Controversy persists over statins and risk of @entity2 . We determined associations of premorbid lipid-lowering therapy and outcomes among @entity0 of the Intensive Blood Pressure Reduction in Acute @entity2 Trials (INTERACT). METHODS: The pooled data of INTERACT 1 and 2 (international, multicenter, prospective, open, blinded end point, randomized controlled trials of @entity0 with @entity2 [<6 hours] and elevated systolic blood pressure) were analyzed with regard to associations of baseline lipid-lowering treatment and clinical outcomes of 3184 @entity0 in a multivariate model. Associations of lipid-lowering therapy and @entity1 growth (baseline to 24 hours) in computed tomographic substudies @entity0 (n=1310) were estimated in ANCOVA. RESULTS: Among 204 @entity0 (6.5%) with baseline lipid-lowering treatment, 90-day clinical outcomes were not significantly different after adjustment for confounding variables including region and age. In the computed tomographic substudy, 24-hour @entity1 growth was greater in 124 @entity0 (9%) with, compared with those without, prior lipid-lowering therapy. However, this association was not significant between groups (9.2 versus 6.8 mL; P<0.13), after adjustment for prior antithrombotic therapy. CONCLUSIONS: No independent associations were found between lipid-lowering medication and adverse outcomes in @entity0 with @entity2 . CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00226096 and NCT00716079.

title: No Relationship of Lipid-Lowering Agents to XXXX Growth: Pooled Analysis of the Intensive Blood Pressure Reduction in Acute @entity2 Trials Studies.

answer: @entity1


abstract: BACKGROUND AND PURPOSE: Controversy persists over statins and risk of @entity2 . We determined associations of premorbid lipid-lowering therapy and outcomes among @entity0 of the Intensive Blood Pressure Reduction in Acute @entity2 Trials (INTERACT). METHODS: The pooled data of INTERACT 1 and 2 (international, multicenter, prospective, open, blinded end point, randomized controlled trials of @entity0 with @entity2 [<6 hours] and elevated systolic blood pressure) were analyzed with regard to associations of baseline lipid-lowering treatment and clinical outcomes of 3184 @entity0 in a multivariate model. Associations of lipid-lowering therapy and @entity1 growth (baseline to 24 hours) in computed tomographic substudies @entity0 (n=1310) were estimated in ANCOVA. RESULTS: Among 204 @entity0 (6.5%) with baseline lipid-lowering treatment, 90-day clinical outcomes were not significantly different after adjustment for confounding variables including region and age. In the computed tomographic substudy, 24-hour @entity1 growth was greater in 124 @entity0 (9%) with, compared with those without, prior lipid-lowering therapy. However, this association was not significant between groups (9.2 versus 6.8 mL; P<0.13), after adjustment for prior antithrombotic therapy. CONCLUSIONS: No independent associations were found between lipid-lowering medication and adverse outcomes in @entity0 with @entity2 . CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00226096 and NCT00716079.

title: No Relationship of Lipid-Lowering Agents to @entity1 Growth: Pooled Analysis of the Intensive Blood Pressure Reduction in Acute XXXX Trials Studies.

answer: @entity2